HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dahlöf, C. Search for Related Content PubMed PubMed Citation Articles by Dahlöf, C.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Clinical applications of new therapeutic deliveries in migraine

From the Gothenburg Migraine Clinic, Gothenburg, Sweden.

Address correspondence and reprint requests to Dr. C. H. Dahlöf, Gothenburg Migraine Clinic, Sociala Huset, Gothenburg SE-411 17, Sweden.

A number of serotonin (5-HT)_1B/1D agonists (triptans) are available worldwide for the treatment of migraine. The first-generation triptan, sumatriptan, was initially launched as an SC injection, which is fast-acting and consistently effective but relatively expensive and can be associated with adverse events in some patients. Sumatriptan was then launched as an oral tablet, shortly followed by the development of second-generation triptans that are now available in several formulations. Tablets are highly effective and convenient but may not be suitable in all migraine situations, e.g., migraine-associated nausea or vomiting and gastric disturbances. An intranasal route of administration appears to be an obvious way to deliver a migraine treatment and two triptans, sumatriptan and zolmitriptan, are available in nasal spray formulations. Sumatriptan offered the first nasal spray and has similar efficacy to the sumatriptan tablet, but the response is inconsistent and many patients cannot tolerate the unpleasant taste. The latest nasal spray, zolmitriptan, has produced exciting results in clinical studies and combines a rapid onset of action and consistently high response rates with a good tolerability profile. Early results from the author’s clinic suggest that this promise is realized in clinical practice and that this combination of patient benefits makes zolmitriptan nasal spray an ideal way for patients to treat their migraine. With the introduction of zolmitriptan nasal spray, zolmitriptan is now available in three different formulations, enabling patients to tailor their treatment to the circumstances of the individual attack.

Publication of this supplement was supported by an unrestricted educational grant from AstraZeneca Pharmaceuticals.

This article has been cited by other articles:

				A. R. Pachner, D. Cadavid, L. Wolansky, and J. Skurnick Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study Neurology, November 3, 2009; 73(18): 1485 - 1492. [Abstract] [Full Text] [PDF]

				R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]

				C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF]

				F Gilli, F Marnetto, M Caldano, A Sala, S Malucchi, M Capobianco, and A Bertolotto Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1 Multiple Sclerosis, February 1, 2006; 12(1): 47 - 57. [Abstract] [PDF]